|
1
|
Brozovic A, Fritz G, Christmann M,
Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of
SAPK/JNK, p38 kinase and fas-L expression by cisplatin is
attenuated in human carcinoma cells that acquired drug resistance.
Int J Cancer. 112:974–985. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Komatsu M, Sumizawa T, Mutoh M, Chen ZS,
Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, et al:
Copper-transporting P-type adenosine triphosphatase (ATP7B) is
associated with cisplatin resistance. Cancer Res. 60:1312–1316.
2000.PubMed/NCBI
|
|
3
|
Taniguchi K, Wada M, Kohno K, Nakamura T,
Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano
M: A human canalicular multispecific organic anion transporter
(cMOAT) gene is overexpressed in cisplatin-resistant human cancer
cell lines with decreased drug accumulation. Cancer Res.
56:4124–4129. 1996.PubMed/NCBI
|
|
4
|
Zhu HJ, Wang JS, Guo QL, Jiang Y and Liu
GQ: Reversal of P-glycoprotein mediated multidrug resistance in
K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol
Pharm Bull. 28:1974–1978. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Zhou JY and Wu GS: ERK-dependent
MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Cancer Res. 67:11933–11941. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi CH, Kim HS, Kweon OS, Lee TB, You HJ,
Rha HS, Jeong JH, Lim DY, Min YD, Kim MS, et al: Reactive oxygen
species-specific mechanisms of drug resistance in
paraquat-resistant acute myelogenous leukemia sublines. Mol Cells.
10:38–46. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali
M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero
DA, et al: DNA repair protein levels vis-à-vis anticancer drug
resistance in the human tumor cell lines of the National Cancer
Institute drug screening program. Anticancer Drugs. 13:511–519.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alberts DS, Martínez ME, Hess LM, Einspahr
JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK,
Salen G, et al: Phoenix and Tucson Gastroenterologist Networks:
Phase III trial of ursodeoxycholic acid to prevent colorectal
adenoma recurrence. J Natl Cancer Inst. 97:846–853. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khare S, Cerda S, Wali RK, von Lintig FC,
Tretiakova M, Joseph L, Stoiber D, Cohen G, Nimmagadda K, Hart J,
et al: Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras
activation, and cyclooxygenase-2 expression in colon cancer. Cancer
Res. 63:3517–3523. 2003.PubMed/NCBI
|
|
11
|
Lim SC, Duong HQ, Choi JE, Lee TB, Kang
JH, Oh SH and Han SI: Lipid raft-dependent death receptor 5 (DR5)
expression and activation are critical for ursodeoxycholic
acid-induced apoptosis in gastric cancer cells. Carcinogenesis.
32:723–731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim SC, Duong HQ, Parajuli KR and Han SI:
Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic
acid-induced apoptosis in SNU601 gastric cancer cells. Oncol Rep.
28:1429–1434. 2012.PubMed/NCBI
|
|
13
|
Iwasaki I, Sugiyama H, Kanazawa S and
Hemmi H: Establishment of cisplatin-resistant variants of human
neuroblastoma cell lines, TGW and GOTO, and their drug
cross-resistance profiles. Cancer Chemother Pharmacol. 49:438–444.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun CL and Chao CC: Cross-resistance to
death ligand-induced apoptosis in cisplatin-selected HeLa cells
associated with overexpression of DDB2 and subsequent induction of
cFLIP. Mol Pharmacol. 67:1307–1314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu H, Choi SM, An CS, Min YD, Kim KC, Kim
KJ and Choi CH: Concentration-dependent collateral sensitivity of
cisplatin-resistant gastric cancer cell sublines. Biochem Biophys
Res Commun. 328:618–622. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martinou JC and Green DR: Breaking the
mitochondrial barrier. Nat Rev Mol Cell Biol. 2:63–67. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsujimoto Y: Cell death regulation by the
Bcl-2 protein family in the mitochondria. J Cell Physiol.
195:158–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeuner A, Pedini F, Signore M, Ruscio G,
Messina C, Tafuri A, Girelli G, Peschle C and De Maria R: Increased
death receptor resistance and FLIPshort expression in polycythemia
vera erythroid precursor cells. Blood. 107:3495–3502. 2006.
View Article : Google Scholar
|
|
20
|
Müllauer L, Gruber P, Sebinger D, Buch J,
Wohlfart S and Chott A: Mutations in apoptosis genes: A
pathogenetic factor for human disease. Mutat Res. 488:211–231.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Perego P, Giarola M, Righetti SC, Supino
R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and
Zunino F: Association between cisplatin resistance and mutation of
p53 gene and reduced bax expression in ovarian carcinoma cell
systems. Cancer Res. 56:556–562. 1996.PubMed/NCBI
|
|
22
|
Degenhardt K, Mathew R, Beaudoin B, Bray
K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al:
Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hippert MM, O'Toole PS and Thorburn A:
Autophagy in cancer: Good, bad, or both? Cancer Res. 66:9349–9351.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Syntichaki P and Tavernarakis N: The
biochemistry of neuronal necrosis: Rogue biology? Nat Rev Neurosci.
4:672–684. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vakkila J and Lotze MT: Inflammation and
necrosis promote tumour growth. Nat Rev Immunol. 4:641–648. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zong WX and Thompson CB: Necrotic death as
a cell fate. Genes Dev. 20:1–15. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bernales S, McDonald KL and Walter P:
Autophagy counterbalances endoplasmic reticulum expansion during
the unfolded protein response. PLoS Biol. 4:e4232006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eisenberg-Lerner A, Bialik S, Simon HU and
Kimchi A: Life and death partners: Apoptosis, autophagy and the
cross-talk between them. Cell Death Differ. 16:966–975. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moretti L, Cha YI, Niermann KJ and Lu B:
Switch between apoptosis and autophagy: Radiation-induced
endoplasmic reticulum stress? Cell Cycle. 6:793–798. 2007.
View Article : Google Scholar : PubMed/NCBI
|
